This month's Brain Capital event aimed to position Houston and Texas as global leaders in the brain economy space. Photo via Getty Images

Brain Capital: The New Competitive Edge in a Shifting Economy, a two-day meeting held at the TMC3 Collaborative Building on May 21-22, brought together global business and policy leaders to advance brain health initiatives. The event concluded with the announcement of Texas-focused strategies that will be presented at the G7 Summit in Calgary this June, aiming to position the state as a leading hub for brain health research.

According to an analysis by the McKinsey Health Institute, investing in brain health interventions has the potential to generate a $260 billion boost to Texas’ GDP. Brain health conditions are responsible for more than $1 trillion in lost productivity globally, and the costs are expected to increase to nearly $16 trillion by 2030, according to organizers of the event.

The Texas Legislature recently passed legislation to establish the Dementia Prevention Research Institute of Texas (DPRIT), which includes a $3 billion investment over 10 years. Leaders at the Brain Capital event announced the launch of an advocacy campaign to foster support for DPRIT, which will appear as a November 2025 ballot measure.

“Our work to deliver better brain health to Texas and the world is only just beginning,” Dr. Jochen Reiser, president of The University of Texas Medical Branch (UTMB) and CEO of the UTMB Health System, said in a news release. “Investing in brain capital means protecting our cognitive health, boosting economic growth and securing a future-ready workforce – goals that we believe Texans will rally behind.”

Additionally, the Center for Houston’s Future also announced its goal to make the brain economy a key part of its new plan for the Houston region, called Vision 2050. The Center for Houston’s Future’s goal is to position Houston to become the global leader in the brain economy space, which will serve as a blueprint for other cities

“Houston has a clear track record leading the transition of industry sectors,” David Gow, CEO of the Center for Houston’s Future, said in a news release. “By launching a focused Brain Economy transition plan, Houston can integrate neuroscience, prevention, workforce resilience and cognitive innovation across sectors – preparing businesses and communities for an AI-driven future. Houston has the talent, infrastructure and vision to lead the nation in the next great economic transformation.”

Gow is the founder and chairman of Gow Media, InnovationMap's parent company.

Speakers at the event included executives from Shell Oil Co., scientists from Johns Hopkins Bloomberg School of Public Health, professors from Rice University, representatives from D.C.-based UsAgainstAlzheimer’s, and others. Learn more here.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."